[Pegylated interferon beta-1a on the Italian market]

[Pegylated interferon beta-1a on the Italian market]

Authors

  • Mario Eandi Editor in chief Farmeconomia. Health Economics and Therapeutic Pathways. Già Ordinario di Farmacologia Clinica, Facoltà di Medicina e Chirurgia, Università di Torino

DOI:

https://doi.org/10.7175/fe.v17i2S.1228

Keywords:

pegInterferon beta-1a, Multiple Sclerosis, Italy

Abstract

[Editorial in Italian]

References

MSIF - Multiple Sclerosis International Federation. Atlas of MS 2013. Accessibile all’indirizzo web: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf (ultimo accesso novembre 2015)

AISM - Associazione Italiana Sclerosi Multipla. Bilancio sociale AISM 2014. Accessibile all’indirizzo web: http://bilanciosociale.aism.it (ultimo accesso novembre 2015)

Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis. The 2013 revisions. Neurology 2014; 83: 278-86; http://dx.doi.org/10.1212/WNL.0000000000000560

Canal N, Ghezzi A, Zaffaroni M. Sclerosi multipla. Attualità e prospettive. Milano: Elsevier Health Sciences, 2011

Howley A, Kremenchutzky M. Pegylated interferons: a nurses’ review of a novel multiple sclerosis therapy. J Neurosci Nurs 2014; 46: 88-96; http://dx.doi.org/10.1097/JNN.0000000000000039

Calabresi PA, Kieseier BC, Arnold DL, et al; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13: 657-65; http://dx.doi.org/10.1016/S1474-4422(14)70068-7

Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 2015; 21: 1025-35; http://dx.doi.org/10.1177/1352458514557986

Downloads

Published

2016-07-26

How to Cite

Eandi, M. (2016). [Pegylated interferon beta-1a on the Italian market]. Farmeconomia. Health Economics and Therapeutic Pathways, 17(2S), 3–4. https://doi.org/10.7175/fe.v17i2S.1228

Issue

Vol. 17 No. 2S (2016)

Section

Editorial

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
  4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>